drugset / Trial / NCT01032083

Summary

The aim of this double-blind, placebo-controlled trial is to establish the clinical and cost effectiveness of an SSRI antidepressant, citalopram, in the management of persistent negative symptoms of schizophrenia over a year.

Timeline

Start
2011-07
Primary completion
2014-12
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Citalopram Small molecule 20 mg
Comparator Citalopram Small molecule 40 mg

Indications